Evidence map›Paper›PMID 39753363›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.

Lena M Unterrainer, Thomas A Hope, Wolfgang P Fendler, Tristan Grogan, Honest Ndlovu, Wesley Armstrong, Francesco Barbato, Matthias R Benz, Matthew B Rettig, Amar U Kishan and 4 more

Abstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Individualized radiotherapy of bone metastases from prostate cancer: time trends and 5-year survival results.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Observational
  17. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  18. PSMA-Targeted radiopharmaceuticals: from diagnosis to risk & quality of life.European journal of nuclear medicine and molecular imaging · 2025
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lena M UnterrainerAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; lunterrainer@mednet.ucla.edu.
Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Wolfgang P FendlerDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Tristan GroganDepartment of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California.
Honest NdlovuDepartment of Nuclear Medicine, University of Pretoria, Pretoria, South Africa.
Wesley ArmstrongAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Francesco BarbatoDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Matthias R BenzAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Matthew B RettigDepartments of Medicine and Urology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Amar U KishanDepartment of Medicine, VA Greater Los Angeles, Los Angeles, California; and.
Mike SathekgeDepartment of Nuclear Medicine, University of Pretoria, Pretoria, South Africa.
Ken HerrmannDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.

Funding

MELT: Modulation of PSMA Expression for Lutetium TherapyR01CA235741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS A · 2019 to 2025
$3.2M
Qualification and Harmonization of PET/MRI for Cancer Clinical TrialsR01CA212148 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS, LAFOREST, RICHARD ANDRE · 2017 to 2022
$2.7M
NCI NIH HHS R01 CA212148NCI NIH HHS R01 CA235741
6 · The paper itself

Abstract

High-volume disease (HVD) and low-volume disease (LVD) definitions in metastatic hormone-sensitive prostate cancer (mHSPC) patients are based on conventional imaging (CI) (CT/MRI with bone scan [BS]) according to CHAARTED criteria. HVD and LVD definitions are associated with overall survival and are used for treatment decisions. It remains unknown how these definitions transfer to prostate-specific membrane antigen (PSMA) PET imaging. The aim of this retrospective multicenter study was to compare the CI-based disease volume criteria to PSMA PET-based volume definitions in a CHAARTED-like cohort.

Indexed as

Prostatic NeoplasmsAgedAged, 80 and overAntigens, SurfaceGlutamate Carboxypeptidase IIHormonesHumansInternationalityMagnetic Resonance ImagingMaleMiddle AgedNeoplasm MetastasisPositron-Emission TomographyPositron Emission Tomography Computed TomographyRetrospective StudiesTumor BurdenAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIHormonesaBSIbone scanCHAARTEDmHSPCPET/CTPSMAwhole-body tumor volume

Identifiers

PMID39753363
PMCPMC13671395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.